Primedica

Primedica was a prominent contract research organization (CRO) that specialized in providing preclinical drug development services to the global pharmaceutical and biotechnology sectors. The company offered a comprehensive suite of services, including toxicology, pharmacology, pathology, and analytical chemistry, designed to support the safety and efficacy evaluation of new drug candidates. Originally operating as a subsidiary of Genzyme Transgenics Corporation, Primedica established a significant footprint in the United States with multiple research facilities. In 2001, the company was acquired by Charles River Laboratories for approximately $52 million in cash and stock. This acquisition allowed Charles River to significantly expand its preclinical service capabilities and transition into a broader drug development services provider. At the time of its acquisition, Primedica was recognized for its expertise in complex safety assessments and regulatory compliance.